Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833453 | 0.95 | TK1 (0.47) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL20879499 | 0.93 | TK1 (0.47) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL24695053 | 0.86 | TK1 (0.50) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL23622010 | 0.85 | TK1 (0.49) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL12060749 | 0.85 | LMNA (0.53) | TK1LMNAADRA1ATSHRPMP22 | |
| SCHEMBL9151712 | 0.83 | TK1 (0.49) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL9151709 | 0.83 | TK1 (0.49) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL20833146 | 0.82 | TK1 (0.47) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL15184742 | 0.82 | TK1 (0.50) | TK1LMNAALBBLMALDH1A1 | |
| SCHEMBL10083240 | 0.82 | TK1 (0.47) | TK1LMNAALBBLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20120034184-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT (GB) | 2012-02-09 | — | — | US | disclosed |
| US-5192749-A | Viricide, AIDS | SYNTEX (U.S.A.) INC. (US) | 1993-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034184-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | TK1 533/4885LMNA 2119/4885ALB 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.